Zou Huimei, Chen Min, Wang Xiuhong, Yu Jie, Li Xiaoying, Xie Ying, Liu Jun, Liu Miao, Xu Lifen, Zhang Qiong, Tian Xiaoxue, Zhang Fan, Guo Bing
Department of Pathophysiology, Guizhou Medical University, Guiyang, PR China.
Guizhou Provincial Key Laboratory of Pathogenesis and Drug Research on Common Chronic Diseases, Guizhou Medical University, Guiyang, PR China.
J Pathol. 2023 Nov;261(3):269-285. doi: 10.1002/path.6174. Epub 2023 Aug 21.
As an essential factor in the prognosis of systemic lupus erythematosus (SLE), lupus nephritis (LN) can accelerate the rate at which patients with SLE can transition to chronic kidney disease or even end-stage renal disease. Podocytes now appear to be a possible direct target in LN in addition to being prone to collateral damage from glomerular capillary lesions induces by immune complexes and inflammatory processes. The NLRP3 inflammasome is regulated by CCAAT/enhancer-binding protein β (C/EBPβ), which is involved in the pathogenesis of SLE. However, the role and mechanism of C/EBPβ in LN remain unclear. In this investigation, glomerular podocytes treated with LN serum and MRL/lpr mice were employed as in vivo and in vitro models of LN, respectively. In vivo, the expression of C/EBPβ isoforms was detected in kidney specimens of humans and mice with LN. Then we assessed the effect of C/EBPβ inhibition on renal structure and function by injecting RNAi adeno-associated virus of C/EBPβ shRNA into MRL/lpr mice. In vitro, glomerular podocytes were treated with LN serum and C/EBPβ siRNA to explore the role of C/EBPβ in the activation of the AIM2 inflammasome and podocyte injury. C/EBPβ-LAP and C/EBPβ-LIP were significantly overexpressed in kidney tissue samples from LN patients and mice, and C/EBPβ inhibition significantly alleviated renal function damage and ameliorated renal structural deficiencies. Inflammatory pathways downstream from the AIM2 inflammasome could be suppressed by C/EBPβ knockdown. Furthermore, the upregulation of C/EBPβ-LAP could activate the AIM2 inflammasome and podocyte pyroptosis by binding to the promoters of AIM2 and CASPASE1 to enhance their expression, and the knockdown of AIM2 or (and) caspase-1 reversed the effects of C/EBPβ-LAP overexpression. Interestingly, C/EBPβ-LIP overexpression could transcriptionally inhibit IRAG and promote Ca release-mediated activation of the AIM2 inflammasome. This finding suggests that C/EBPβ is not only involved in the regulation of the expression of key proteins of the AIM2 inflammasome but also affects the polymerization of key proteins of the AIM2 inflammasome through the regulation of Ca release. In conclusion, this study provides a new idea for studying the regulatory mechanism of C/EBPβ and provides a theoretical basis for the early diagnosis and treatment of LN in the future. © 2023 The Pathological Society of Great Britain and Ireland.
作为系统性红斑狼疮(SLE)预后的一个关键因素,狼疮性肾炎(LN)会加快SLE患者发展为慢性肾脏病甚至终末期肾病的速度。足细胞现在似乎是LN中一个可能的直接靶点,此外还容易受到免疫复合物和炎症过程诱导的肾小球毛细血管病变的间接损伤。NLRP3炎性小体受CCAAT/增强子结合蛋白β(C/EBPβ)调控,C/EBPβ参与SLE的发病机制。然而,C/EBPβ在LN中的作用和机制仍不清楚。在本研究中,分别采用LN血清处理的肾小球足细胞和MRL/lpr小鼠作为LN的体内和体外模型。在体内,检测了LN患者和小鼠肾脏标本中C/EBPβ亚型的表达。然后,通过向MRL/lpr小鼠注射C/EBPβ shRNA的RNAi腺相关病毒,评估C/EBPβ抑制对肾脏结构和功能的影响。在体外,用LN血清和C/EBPβ siRNA处理肾小球足细胞,以探讨C/EBPβ在AIM2炎性小体激活和足细胞损伤中的作用。C/EBPβ-LAP和C/EBPβ-LIP在LN患者和小鼠的肾脏组织样本中显著过表达,抑制C/EBPβ可显著减轻肾功能损害并改善肾脏结构缺陷。敲低C/EBPβ可抑制AIM2炎性小体下游的炎症信号通路。此外,C/EBPβ-LAP的上调可通过与AIM2和CASPASE1的启动子结合以增强它们的表达,从而激活AIM2炎性小体和足细胞焦亡,敲低AIM2或(和)caspase-1可逆转C/EBPβ-LAP过表达的作用。有趣的是,C/EBPβ-LIP的过表达可转录抑制IRAG并促进Ca释放介导的AIM2炎性小体激活。这一发现表明,C/EBPβ不仅参与AIM2炎性小体关键蛋白表达的调控,还通过调节Ca释放影响AIM2炎性小体关键蛋白的聚合。总之,本研究为研究C/EBPβ的调控机制提供了新思路,并为未来LN的早期诊断和治疗提供了理论依据。© 2023英国和爱尔兰病理学会